Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Inclusion Criteria:

   - Histologically confirmed Hodgkin's lymphoma at time of relapse or disease progression,
   meeting all of the following criteria:

      - Stage I-IV disease

      - No morphologically unclassifiable disease

   - Meets 1 of the following criteria:

      - Mixed cellularity

      - Lymphocytic depletion (LD)

      - LD, diffuse fibrosis

      - LD, reticular

      - Lymphocyte predominance (LP)

      - LP, diffuse

      - LP, nodular

      - Nodular sclerosis (NS)

      - NS, cellular phase

      - NS, lymphocytic predominance

      - NS, mixed cellularity

      - NS, LD

      - Not otherwise specified

   - Primary refractory disease OR disease in first relapse, except for the following:

      - Patients who achieved a complete response after treatment on protocol
      COG-AHOD0431 who experience a biopsy-proven recurrence after doxorubicin
      hydrochloride, vincristine, prednisone, and cyclophosphamide without
      involved-field radiotherapy

      - Patients on the observation-only arm of protocol COG-AHOD0431

   - Any measurable, focal mass lesion of a visceral organ (e.g., liver, spleen, or kidney)

   - Patients with metastatic disease to bone marrow and granulocytopenia, anemia, and/or
   thrombocytopenia are allowed provided both of the following criteria are met:

      - Platelet count ≥ 20,000/mm³ (platelet transfusion allowed)

      - Hemoglobin ≥ 8 g/dL (packed red blood cell transfusion allowed)

   - Karnofsky performance status (PS) 60-100% (for patients > 16 years of age) OR Lanksy
   PS 60-100% (for patients =< 16 years of age)

   - Life expectancy >= 2 months

   - Absolute neutrophil count >= 1,000/mm^3

   - Platelet count >= 75,000/mm^3 (transfusion independent) (for patients with no bone
   marrow involvement)

   - Creatinine =< 1.5 times upper limit of normal (ULN)

   - Creatinine clearance or radioisotope glomerular filtration rate >= 70 mL/min/1.73 m^2

   - AST and ALT =< 2.5 times ULN

   - Bilirubin =< 1.5 times ULN

   - Shortening fraction >= 27% by echocardiogram OR LVEF >= 50% by gated radionuclide
   study

   - Patients with a seizure disorder are eligible if on a nonenzyme-inducing
   anticonvulsant and seizures are well controlled

   - No CNS toxicity > grade 2

   - No serious intercurrent illnesses

   - No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or any
   component of the study drugs

   - No peripheral neuropathy > grade 1

   - No known hypersensitivity to bortezomib, boron, or mannitol

   - No other concurrent chemotherapy or immunomodulating agents (including steroids)

      - Concurrent corticosteroids allowed for treatment or prophylaxis of anaphylactic
      reactions

      - No dexamethasone or aprepitant as an antiemetic

   - Not pregnant or nursing

   - Negative pregnancy test

   - Fertile patients must use effective contraception

   - Recovered from prior therapy

   - No prior bortezomib or other proteasome inhibitors

   - At least 3 weeks since prior chemotherapy (4 weeks for nitrosoureas)

   - More than 14 days since prior investigational drugs

   - No concurrent enzyme inducing anticonvulsants that alter p450 metabolism, including
   phenytoin, carbamazepine, phenobarbital, or other anticonvulsants

      - Benzodiazepine or gabapentin allowed